Sandra K. Kostyk
Neuroscience · The Ohio State University
Publications
85
Citations
6,438
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1978
Sandra K. Kostyk's research focuses on Huntington's disease and related movement disorders, particularly clinical trials testing new drug treatments for symptoms like chorea (involuntary movements), cognitive decline, and motor function loss. Her work also extends to gait, balance, and mobility interventions in Parkinson's disease and Lewy body dementia. Much of her recent output involves large multi-site clinical trials evaluating drugs such as pridopidine, valbenazine, and pepinemab.
Publication output has fluctuated over the past decade but shows a recent uptick, with the highest yearly counts occurring in 2024 and 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Pridopidine in early-stage manifest Huntington’s disease: a phase 3 trial
Nature Medicine · 2025
- Improving the Clinical Diagnostic Criteria for Genetically Confirmed Adult-Onset Huntington Disease
Neurology Clinical Practice · 2025
- Antidopaminergic Medications Are Associated with Faster Decline in Measures of Clinical Outcome in HD: Insights from PROOF-HD
medRxiv · 2025
- The Phase 3 PROOF-HD Trial Demonstrates Meaningful Benefits of Pridopidine on Function, Cognition, and Motor Signs in Huntington Disease (HD) (PL5.002)
Neurology · 2025
- The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease (HD)
Neurotherapeutics · 2025
- Use of a Robotic Walking Device for Home and Community Mobility in Parkinson Disease: A Randomized Controlled Trial
Journal of Neurologic Physical Therapy · 2024
- Analyses of the Phase 3 Trial of Pridopidine’s Outcome on Function in Huntington Disease (PROOF-HD) Demonstrates Efficacy in Participants Without Antidopaminergic Medications (S30.002)
Neurology · 2024
- Refining the Language of Huntington’s Disease Progression with the Huntington’s Disease Integrated Staging System (HD-ISS)
Journal of Huntington s Disease · 2024
- What Huntington’s Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study
Journal of Huntington s Disease · 2024
- J008 The phase 3 proof-hd trial demonstrates benefits of pridopidine on progression in Huntington Disease
2024
- F034 The flamingo study: single leg stance time provides unique insight to motor progression in Huntington’s disease
2024
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Neurology · 2023
- Elsevier - Best research paper: Topline results of the PROOF-HD pivotal phase 3 trial: Pridopidine's outcome on function in Huntington disease
Journal of the Neurological Sciences · 2023
- Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Nature Medicine · 2022
- J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)
2022
- Neurology×7
- Nature Medicine×3
- Journal of Huntington s Disease×3
- Gait & Posture×2
- Journal of Neurology Neurosurgery & Psychiatry×2
- Deb Kegelmeyer
Neuroscience · The Ohio State University
- Anne Kloos
Neuroscience · The Ohio State University
- David D. Bushart
Neuroscience · The Ohio State University
- Chad Hoyle
Neuroscience · The Ohio State University
- Jing Yang
Neuroscience · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile